Recommendations for standardized pathological characterization of residual disease for neoadjuvant clinical trials of breast cancer by the BIG-NABCG collaboration
Veerle Bossuyt(Yale University), Elena Provenzano(University of Cambridge), W. Fraser Symmans(The University of Texas MD Anderson Cancer Center), Judy C. Boughey(Mayo Clinic), Charlotte E. Coles(National Health Service), Giuseppe Curigliano(European Institute of Oncology), J. Michael Dixon(Western General Hospital), Laura J. Esserman(University of California, San Francisco), Gerd Fastner(Paracelsus Medical University), Thorsten Kuehn(Klinikum Esslingen), Florentia Peintinger(Medical University of Graz), Gϋnter von Minckwitz(German Breast group), Julia White(The Ohio State University), Wei Yang(The University of Texas MD Anderson Cancer Center), Sunil Badve(Indiana University School of Medicine), Carsten Denkert(Charité - Universitätsmedizin Berlin), Gaëtan MacGrogan(Institut Bergonié), Frédérique Penault‐Llorca(Université Clermont Auvergne), Giuseppe Viale(University of Milan), David Cameron(Edinburgh Cancer Research), Helena Earl, Emilio Alba, Aňa Lluch, Joan Albanell, Keith D. Amos, Wojciech Biernat, Hervé Bonnefoi, Aman U. Buzdar, Paul Cane, Sarah E. Pinder, L. F. Carson, Diana Dickson-Witmer, Gyungyub Gong, Jimmy Green, Chih‐Yi Hsu, Ling‐Ming Tseng, Judith R. Kroep, A. Marilyn Leitch, Venetia Sarode, E. Mamounas, P. Kelly Marcom, Paolo Nucíforo, Soonmyung Paik, Vicente Peg, David Peston, Jean‐Yves Pierga, Miguel Quintela-Fandiño, Roberto Salgado, William M. Sikov, Jeremy Thomas, Gary Unzeitig, Jelle Wesseling
Cited by 237Open Access
Abstract
Related Papers
No related papers found
Powered by citation graph analysis